Technical Analysis for IFRX - InflaRx N.V.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | 0.00% | |
200 DMA Support | Bullish | 0.00% | |
50 DMA Support | Bullish | 0.00% | |
BB Squeeze Ended | Range Expansion | 0.00% | |
20 DMA Support | Bullish | 1.94% | |
200 DMA Support | Bullish | 1.94% | |
50 DMA Support | Bullish | 1.94% | |
Bollinger Band Squeeze | Range Contraction | 1.94% | |
Outside Day | Range Expansion | 1.94% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.64% |
Alert | Time |
---|---|
200 DMA Support | about 22 hours ago |
10 DMA Resistance | 1 day ago |
20 DMA Support | 1 day ago |
50 DMA Support | 1 day ago |
Rose Above 10 DMA | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 08/08/2024
InflaRx N.V. Description
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Immunology Immune System Autoimmune Disease Clinical Development Antibodies Monoclonal Antibodies Monoclonal Antibody Inflammatory Diseases Complement System Hidradenitis Suppurativa C5a
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.1 |
52 Week Low | 1.14 |
Average Volume | 74,248 |
200-Day Moving Average | 1.53 |
50-Day Moving Average | 1.53 |
20-Day Moving Average | 1.53 |
10-Day Moving Average | 1.56 |
Average True Range | 0.09 |
RSI (14) | 55.36 |
ADX | 16.71 |
+DI | 15.59 |
-DI | 20.06 |
Chandelier Exit (Long, 3 ATRs) | 1.44 |
Chandelier Exit (Short, 3 ATRs) | 1.70 |
Upper Bollinger Bands | 1.61 |
Lower Bollinger Band | 1.45 |
Percent B (%b) | 0.79 |
BandWidth | 10.39 |
MACD Line | 0.02 |
MACD Signal Line | 0.01 |
MACD Histogram | 0.0035 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.70 | ||||
Resistance 3 (R3) | 1.69 | 1.65 | 1.68 | ||
Resistance 2 (R2) | 1.65 | 1.62 | 1.65 | 1.67 | |
Resistance 1 (R1) | 1.61 | 1.60 | 1.63 | 1.62 | 1.67 |
Pivot Point | 1.57 | 1.57 | 1.58 | 1.57 | 1.57 |
Support 1 (S1) | 1.53 | 1.54 | 1.55 | 1.54 | 1.49 |
Support 2 (S2) | 1.49 | 1.52 | 1.49 | 1.49 | |
Support 3 (S3) | 1.45 | 1.49 | 1.48 | ||
Support 4 (S4) | 1.46 |